medigraphic.com

2023, Número 3

<< Anterior Siguiente >>

Enf Infec Microbiol 2023; 43 (3)


Peritonitis bacteriana espontánea: la evolución de una patología infecciosa importante

Esparza AS, Mora GO, Pérez GHR, González DE, Pérez SCJ, Vázquez LM, Morfín OR, Rodríguez NE

Idioma: Español
Referencias bibliográficas: 46
Paginas: 101-105
Archivo PDF: 130.86 Kb.


RESUMEN

La peritonitis bacteriana espontánea (PBE) es una infección grave, que con frecuencia ocurre en pacientes que padecen daño hepático crónico, cirrosis y presencia de líquido ascítico. Ésta se manifiesta en pacientes con trastornos inmunológicos significativos, alteraciones en la microbiota intestinal y disfunción de la barrera de la mucosa intestinal. Los agentes bacterianos comunes son bacilos Gram negativos como Escherichia coli. La presencia de bacterias multirresistentes como Klebsiella pneumoniae complica la selección de la terapia antimicrobiana. Generalmente el diagnóstico se realiza mediante la detección de más de 250 neutrófilos por milímetro cúbico en líquido ascítico. El tratamiento es multidisciplinario, debe incluir antibioticoterapia, el manejo de la ascitis, de la hipoalbuminemia y del síndrome hepatorrenal.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bhat, C., Reinglas, J. y Costain, N., “Spontaneous bacterialperitonitis in cirrhosis”, cmaj, 2023, 195 (3): E120.

  2. Bhandari, R., Khaliq, K., Ravat, V., Kaur, P. y Patel, R.S.,“Chronic alcoholic liver disease and mortality risk inspontaneous bacterial peritonitis: analysis of 6,530 hospitalizations”,Cureus, 2020, 12 (5): e8189.

  3. Abu-Freha, N., Michael, T., Poupko, L. et al., “Spontaneousbacterial peritonitis among cirrhotic patients:prevalence, clinical characteristics, and outcomes”, JClin Med, 2021, 11 (1).

  4. Biggins, S.W., Angeli, P., García-Tsao, G. et al., “Diagnosis,evaluation, and management of ascites, spontaneousbacterial peritonitis and hepatorenal syndrome:2021 practice guidance by the American Association forthe Study of Liver Diseases”, Hepatology, 2021, 74 (2):1014-1048.

  5. Hirode, G., Saab, S. y Wong, R.J., “Trends in the burdenof chronic liver disease among hospitalized US adults”,jama Netw Open, 2020, 3 (4): e201997.

  6. Whipple, R.L., Jr., y Harris, J.F., “B. coli septicemia inLaennec’s cirrhosis of the liver”, Ann Intern Med, 1950,33 (2): 462-466.

  7. Martin, W.J., Spittel, J.A., Morlock, C.G. y Baggenstoss,A.H., “Severe liver disease complicated by bacteremiadue to gramnegative bacilli”, ama Arch Intern Med,1956, 98 (1): 8-15.

  8. Caroli, J. y Platteborse, R., “Septicemie porto-cave: cirrhosesdu foi at septicemie a colibacilli”, Sem Hop Paris,1958, 34: 472-487.

  9. Kerr, D.N., Pearson, D.T. y Read, A.E., “Infection of asciticfluid in patients with hepatic cirrhosis”, Gut, 1963, 4(4): 394-398.

  10. Conn, H.O., “Spontaneous peritonitis and bacteremia inLaennec’s cirrhosis caused by enteric organisms. a relativelycommon but rarely recognized syndrome”, AnnIntern Med, 1964, 60: 568-580.

  11. Bajaj, J.S., Kamath, P.S. y Reddy, K.R., “The evolving challengeof infections in cirrhosis”, N Engl J Med, 2021,384 (24): 2317-2330.

  12. Piano, S., Singh, V., Caraceni, P. et al., “Epidemiology andeffects of bacterial infections in patients with cirrhosisworldwide”, Gastroenterology, 2019, 156 (5): 1368-1380e10.

  13. Li, H., Wieser, A., Zhang, J. et al., “Patients with cirrhosisand sbp: increase in multidrug-resistant organismsand complications”, Eur J Clin Invest, 2020, 50 (2):e13198.

  14. Tandon, P., Delisle, A., Topal, J.E. y García-Tsao, G., “Highprevalence of antibiotic-resistant bacterial infectionsamong patients with cirrhosis at a US liver center”, ClinGastroenterol Hepatol, 2012, 10 (11): 1291-1298.

  15. Ghweil, A.A., Bazeed, S.E.S., Al Rawy, M.H., Khodeary,A. y El-Amir, M.I., “Fluoroquinolone-resistant strains incirrhotic patients with spontaneous bacterial peritonitis:microbiological and molecular aspects”, Eur J GastroenterolHepatol, 2022, 34 (1): 64-68.

  16. Zhu, L.C., Wu, W., Zou, B. et al., “Efficacy predictorsof third-generation cephalosporins in treating spontaneousbacterial peritonitis”, Medicine (Baltimore), 2022,101 (40): e30164.

  17. Jalan, R., Fernández, J., Wiest, R. et al., “Bacterial infectionsin cirrhosis: a position statement based on theeasl Special Conference 2013”, J Hepatol, 2014, 60 (6):1310-1324.

  18. Boustany, A., Rahhal, R., Onwuzo, S. et al., “Cirrhotic patientson proton pump inhibitors are at a twofold risk ofspontaneous bacterial peritonitis independently of gastrointestinalbleeding: a population-based retrospectivestudy”, Ann Gastroenterol, 2023, 36 (3): 327-332.

  19. Dahabra, L., Kreidieh, M., Abureesh, M., Abou Yassine,A. y Deeb, L., “Proton pump inhibitors use and increasedrisk of spontaneous bacterial peritonitis in cirrhoticpatients: a retrospective cohort analysis”, GastroenterologyRes, 2022, 15 (4): 180-187.

  20. Zhang, M., Liu, W., Xu, X., Chen, T. y Qi, J.Y., “Associationbetween proton pump inhibitor therapy and spontaneousbacterial peritonitis occurrence in cirrhotic patients: a clinicalreview”, Curr Med Sci, 2022, 42 (4): 673-680.

  21. Coxeter-Smith, C., Al-Adhami, A. y Alrubaiy, L., “Theusefulness of mayo end-stage liver disease (meld) andmeld-sodium (meld-na) scores for predicting mortality incirrhotic patients with spontaneous bacterial peritonitis”,Cureus, 2023, 15 (4): e38343.

  22. Runyon, B.A., “Introduction to the revised American Associationfor the Study of Liver Diseases Practice Guidelinemanagement of adult patients with ascites dueto cirrhosis 2012”, Hepatology, 2013, 57 (4): 1651-1653.

  23. Pieri, G., Agarwal, B. y Burroughs, A.K., “C-reactive proteinand bacterial infection in cirrhosis”, Ann Gastroenterol,2014, 27 (2): 113-120. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24733601.

  24. Verma, R., Satapathy, S.K. y Bilal, M., “Procalcitonin andc-reactive protein in the diagnosis of spontaneous bacterialperitonitis”, Transl Gastroenterol Hepatol, 2022, 7: 36.

  25. Patel, K.P., Gallagher, J.P., Korbitz, P.M. et al., “Performanceof leukocyte esterase reagent strips in the detectionof spontaneous bacterial peritonitis in cirrhotic patients:a systematic review and meta-analysis”, J Clin Exp Hepatol,2022, 12 (2): 519-532.

  26. Patel, K.P., Korbitz, P.M., Gallagher, J.P., Schmidt, C.,Ingviya, T. y Manatsathit, W., “Ascitic calprotectin andlactoferrin for detection of spontaneous bacterial peritonitis:a systematic review and meta-analysis”, TranslGastroenterol Hepatol, 2022, 7: 37.

  27. Seyedi, S.A., Nabipoorashrafi, S.A., Hernández, J. et al.,“Neutrophil to lymphocyte ratio and spontaneous bacterialperitonitis among cirrhotic patients: a systematicreview and meta-analysis”, Can J Gastroenterol Hepatol,2022, 2022: 8604060.

  28. Lotte, R., Courdurie, A., Gaudart, A. et al., “Spontaneousbacterial peritonitis: the incremental value of a fast anddirect bacterial identification from ascitic fluids inoculatedin blood culture bottles by maldi-tof ms for a bettermanagement of patients”, Microorganisms, 2022, 10 (6).

  29. Xiang, S., Tan, J., Tan, C. et al., “Establishment and validationof a non-invasive diagnostic nomogram to identifyspontaneous bacterial peritonitis in patients withdecompensated cirrhosis”, Front Med (Lausana), 2021,8: 797363.

  30. Juanola, A., Tiwari, N., Sole, C., Adebayo, D., Wong, F.y Gines, P., “Organ dysfunction and failure in liver disease”,Liver Int, 2023.

  31. Kim, S.W., Yoon, J.S., Park, J. et al., “Empirical treatmentwith carbapenem vs third-generation cephalosporin fortreatment of spontaneous bacterial peritonitis”, ClinGastroenterol Hepatol, 2021, 19 (5): 976-986 e5.

  32. Fernández, J., Acevedo, J., Castro, M. et al., “Prevalenceand risk factors of infections by multiresistant bacteriain cirrhosis: a prospective study”, Hepatology, 2012, 55(5): 1551-1561.

  33. Piano, S., Fasolato, S., Salinas, F. et al., “The empiricalantibiotic treatment of nosocomial spontaneous bacterialperitonitis: results of a randomized, controlled clinicaltrial”, Hepatology, 2016, 63 (4): 1299-1309.

  34. Caraceni, P., Riggio, O., Angeli, P. et al., “Long-termalbumin administration in decompensated cirrhosis(answer): an open-label randomised trial”, Lancet, 2018,391 (10138): 2417-2429.

  35. China, L., Freemantle, N., Forrest, E. et al., “A randomizedtrial of albumin infusions in hospitalized patientswith cirrhosis”, N Engl J Med, 2021, 384 (9): 808-817.

  36. Elfert, A., Abo Ali, L., Soliman, S., Ibrahim, S. y Abd-Elsalam,S., “Randomized-controlled trial of rifaximin versusnorfloxacin for secondary prophylaxis of spontaneousbacterial peritonitis”, Eur J Gastroenterol Hepatol, 2016,28 (12): 1450-1454.

  37. Salehi, S., Tranah, T.H., Lim, S. et al., “Rifaximin reducesthe incidence of spontaneous bacterial peritonitis,variceal bleeding and all-cause admissions in patientson the liver transplant waiting list”, Aliment PharmacolTher, 2019, 50 (4): 435-441.

  38. Collette, K., Bethea, A., Schadler, A. y Kelley, J.L., “Outcomesin patients with spontaneous bacterial peritonitisutilizing first-line or alternative agents for secondary prophylaxis”,Am J Health Syst Pharm, 2023.

  39. Komolafe, O., Roberts, D., Freeman, S.C. et al., “Antibioticprophylaxis to prevent spontaneous bacterialperitonitis in people with liver cirrhosis: a network meta-analysis”, Cochrane Database Syst Rev, 2020, 1 (1):cd013125.

  40. Badal, B.D., Silvey, S., Dragilev, L. et al., “Primary prophylaxisfor spontaneous bacterial peritonitis is linkedto antibiotic resistance in the Veterans Health Administration”,Hepatology, 2023.

  41. Huang, C.H., Wang, S.F., Lee, C.H. et al., “Bacteremia(sepsis), hepatorenal syndrome, and serum creatininelevels rather than types or microbial patterns predictedthe short-term survival of cirrhotic patients complicatedwith spontaneous bacterial peritonitis”, Diagnostics (Basilea),2022, 13 (1).

  42. Dahiya, D.S., Sanaka, M.R., Kichloo, A. et al., “Early readmissionsof spontaneous bacterial peritonitis in theUSA: insights into an emerging challenge”, J GastroenterolHepatol, 2022, 37 (11): 2067-2073.

  43. Pimentel, R., Leitao, J., Gregorio, C., Santos, L., Carvalho,A. y Figueiredo, P., “Spontaneous bacterial peritonitisin cirrhotic patients: a shift in the microbial pattern?A retrospective analysis”, ge Port J Gastroenterol, 2022,29 (4): 256-266.

  44. El Shamy, R.M., Oda, M.S., Saeed, M.A. y Ramadan,R.A., “A comparative study on nosocomial and community-acquired spontaneous bacterial peritonitis inpatients with liver cirrhosis at a university hospital”, EurJ Gastroenterol Hepatol, 2022, 34 (6): 655-663.

  45. Furey, C., Zhou, S., Park, J.H. et al., “Impact of bacteriatypes on the clinical outcomes of spontaneous bacterialperitonitis”, Dig Dis Sci, 2023, 68 (5): 2140-2148.

  46. Khan, S. y Linganna, M., “Diagnosis and managementof ascites, spontaneous bacterial peritonitis, and hepatorenalsyndrome”, Cleve Clin J Med, 2023, 90 (4):209-213.




2020     |     www.medigraphic.com